Interview: Carl Firth, CEO, ASLAN Pharmaceuticals, Taiwan
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
ASLAN is an Asia enabled pharmaceutical company that develops novel medicines for global markets.
1. ASLAN inlicenses preclinical drugs that are up to 6-12 months from the clinic
2. ASLAN uses its own financial resources and high quality CRO facilities to perform preclinical, Phase 1 and 2 studies on the partnered compounds
3. ASLAN gets Proof of Concept (PoC) for the partnered compounds in Asia
4. ASLAN outlicenses PoC compounds back to partner for global development and launch
Walsin Xinyi Building, 11/F
No. 1, Songzhi Road
Taipei 11047, Taiwan 11047
Tel: +886 2 8729 2180
Fax: +886 2 8729 2333
http://www.aslanpharma.com/index.html
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
As President of the Taiwan Clinical Research Association (TCRA), Tina Sun brings 25 years of pharmaceutical industry experience to bear on the evolution of Taiwan’s clinical research ecosystem. This interview…
Nick Wang, General Manager of Daiichi Sankyo Taiwan, has more than 25 years’ experience across clinical research and commercial leadership. Since joining the company in 2020, he has led the…
Taiwan is entering a pivotal phase in its healthcare evolution, and Roche’s leaders in Taiwan outline how the convergence of global expertise, advanced diagnostics and innovative therapeutics can accelerate that…
Vivian Kuo, General Manager at UCB, brings over two decades of pharmaceutical industry expertise across medical affairs, marketing, corporate strategy and commercial excellence. Having spent seven years at UCB, progressing…
Lian-Yu Chen, Director General of Taiwan’s National Health Insurance Administration, combines expertise in clinical psychiatry, public health, and governmental leadership. A PhD graduate of Johns Hopkins Bloomberg School of Public…
Under Dave Huang’s leadership, Ferring Taiwan has evolved from organisational recovery to sustained performance and regional relevance. The discussion that follows examines how disciplined focus, early engagement with innovation, and…
Hung Lai Wu, Chairperson of the Taiwan Alliance of Patients’ Organisations (TAPO) and a home dialysis patient for 18 years, has transformed personal experience into systemic advocacy. Since becoming a…
Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She…
How leadership choices translate into lasting impact is the central theme of this conversation with Grant Hu. From reshaping Eisai Taiwan’s organisation to navigating access, innovation, and policy engagement, the…
Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech,…
PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren…
Yenchen Huang, Head of Investment, VP at Diamond Biofund, one of Taiwan’s pioneering evergreen venture capital funds focused on life sciences, our interviewee brings a unique perspective combining scientific training…
See our Cookie Privacy Policy Here
